Goldman Sachs Aktienanleihe BAYN .../ DE000GG2Q4Z7 /
| 2024-04-26 9:23:16 AM | Chg.-0.04 | Bid10:00:40 PM | Ask10:00:40 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 100.04EUR | -0.04% | - Bid Size: - |
- Ask Size: - |
BAYER AG NA O.N. | 20.00 - | 2024-06-26 | Call |
GlobeNewswire
04-18
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
04-16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
04-11
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
03-25
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
03-06
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
03-04
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
02-15
2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire
02-13
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire
02-13
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
GlobeNewswire
01-05
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)
GlobeNewswire
01-04
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary end...
GlobeNewswire
2023-12-14
Iktos and Bayer Announce Collaboration to expand the use of Artificial Intelligence to Design New Su...
GlobeNewswire
2023-12-06
NFWF Announces $4.1 Million in Grants to Conserve the Monarch Butterfly and Other Insect Pollinators
